Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Maintains Target Price $2
Buy Rating on Lipella Pharmaceuticals Backed by Promising Phase 2a Results for Oral Lichen Planus Treatment
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Maintains Target Price $2
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Maintains Target Price $2
Buy Rating Affirmed: Lipella Pharmaceuticals' Innovative Drug Delivery and Clinical Advancements Propel Optimism
Buy Rating Affirmed for Lipella Pharmaceuticals on LP-310's Phase 2a Enrollment and Strategic Advantages
Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Maintains Target Price $2
Analysts Are Bullish on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Lipella Pharmaceuticals, Inc. (LIPO)
Lipella Pharmaceuticals (LIPO.US) was first covered by Maxim Group and given a buy rating, with a target price of $2.00.
Lipella Pharmaceuticals Analyst Ratings